Kidney outcomes and safety of sodium-glucose cotransporter-2 inhibitor therapy in autosomal dominant polycystic kidney disease: systematic review and meta-analysis
Pooled result · Rate of eGFR decline vs pre-SGLT2i slopeResult — go to the resultMean difference 0.65 mL/min/1.73 m² per year 95% CI 0.05–1.26Authors' conclusion
Current evidence is insufficient to establish a beneficial effect of SGLT2 inhibitors on kidney outcomes in patients with ADPKD.
Study context
- Population
- Patients with autosomal dominant polycystic kidney disease (ADPKD)
- Participants
- 451 patients6 clinical studies
- Comparison
- SGLT2i therapy vs placebo / non-SGLT2i therapy / pre-SGLT2i slope
- Outcome
- Rate of eGFR decline vs pre-SGLT2i slope
- Follow-up
- First year
Methodological detailsPRISMA guidelines, predominantly observational studies, Searched PubMed, Scopus, Web of Science, Cochrane Library and Ovid MEDLINE
- PRISMA guidelines
- Predominantly observational studies
- Searched PubMed, Scopus, Web of Science, Cochrane Library and Ovid MEDLINE
Pooled result
As reported in the abstract
Mean difference
0.65 mL/min/1.73 m² per year
95% CI 0.05–1.26
SGLT2ivs Placebo
mean difference 0.65 mL/min/1.73 m² per year (95% CI 0.05–1.26)
Further pooled results
| Outcome | Mean difference (mL/min/1.73 m² per year) (95% CI) | |
|---|---|---|
| eGFR slope change, SGLT2ivs non-SGLT2i therapy · first yearNo improvement | 2.12 (−8.13-12.38) | |
| −10−5051015Difference, mL/min/1.73 m² per year (linear scale) |
| Outcome | Mean difference (mL per year) (95% CI) | |
|---|---|---|
| Total kidney volume change | −31.31 (−184.00-121.37) | |
| −200−1000100200Difference, mL per year (linear scale) |
Original publication
Kidney outcomes and safety of sodium-glucose cotransporter-2 inhibitor therapy in autosomal dominant polycystic kidney disease: systematic review and meta-analysis. Diabetes Res Clin Pract. Published 12 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →